Singapore Clinical Trial: A multicenter, randomized, participant- and investigator - blinded, placebo-controlled, phase 2a study to assess the efficacy, safety and tolerability of GIA632 in adult participants with moderate to severe atopic dermatitis

Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A multicenter, randomized, participant- and investigator - blinded, placebo-controlled, phase 2a study to assess the efficacy, safety and tolerability of GIA632 in adult participants with moderate to severe atopic dermatitis'. The following are the other relevant details related to the trial:

Therapeutic Area: Dermatology

Trial Centre(s): National Skin Centre National University Hospital Singapore General Hospital

Trial Status: NA

Principal Investigator(s): Dr Yew Yik Weng Dr Nisha Suyien Chandran Dr Lee Haur Yueh

Published by HT Digital Content Services with permission from Health Daily Digest....